中国药物警戒
中國藥物警戒
중국약물경계
CHINESE JOURNAL OF PHARMACOVIGILANCE
2014年
9期
531-535
,共5页
蔡垠%朱金莲%武利%周志亮%苗艳%戴林东
蔡垠%硃金蓮%武利%週誌亮%苗豔%戴林東
채은%주금련%무리%주지량%묘염%대림동
阿托伐他汀钙%阿托伐他汀钙杂质H%溶出度%累积溶出量(%)%校正因子
阿託伐他汀鈣%阿託伐他汀鈣雜質H%溶齣度%纍積溶齣量(%)%校正因子
아탁벌타정개%아탁벌타정개잡질H%용출도%루적용출량(%)%교정인자
atorvastatin calcium%atorvastatin related compound H%dissolution%cumulative release amount (%)%correction factor
目的:建立阿托伐他汀钙片溶出度研究方法。方法色谱柱:Agilent TC-C18(4.6×250 mm,5μm);以乙腈:四氢呋喃:0.05 M柠檬酸铵缓冲液(pH 4.0)=27:20:53为流动相;检测波长:244 nm;流速:1.5 mL·min-1;以阿托伐他汀钙与阿托伐他汀钙杂质H峰面积之和计算累积溶出量(%);结果阿托伐他汀钙在pH 1.0盐酸溶液、醋酸-醋酸铵缓冲液(pH 4.5)中不稳定,降解生成阿托伐他汀钙杂质H,阿托伐他汀钙片在pH 1.0盐酸溶液中溶出速率最慢;结论阿托伐他汀钙在pH 1.0盐酸溶液中溶出曲线可作为处方筛选的依据。
目的:建立阿託伐他汀鈣片溶齣度研究方法。方法色譜柱:Agilent TC-C18(4.6×250 mm,5μm);以乙腈:四氫呋喃:0.05 M檸檬痠銨緩遲液(pH 4.0)=27:20:53為流動相;檢測波長:244 nm;流速:1.5 mL·min-1;以阿託伐他汀鈣與阿託伐他汀鈣雜質H峰麵積之和計算纍積溶齣量(%);結果阿託伐他汀鈣在pH 1.0鹽痠溶液、醋痠-醋痠銨緩遲液(pH 4.5)中不穩定,降解生成阿託伐他汀鈣雜質H,阿託伐他汀鈣片在pH 1.0鹽痠溶液中溶齣速率最慢;結論阿託伐他汀鈣在pH 1.0鹽痠溶液中溶齣麯線可作為處方篩選的依據。
목적:건립아탁벌타정개편용출도연구방법。방법색보주:Agilent TC-C18(4.6×250 mm,5μm);이을정:사경부남:0.05 M저몽산안완충액(pH 4.0)=27:20:53위류동상;검측파장:244 nm;류속:1.5 mL·min-1;이아탁벌타정개여아탁벌타정개잡질H봉면적지화계산루적용출량(%);결과아탁벌타정개재pH 1.0염산용액、작산-작산안완충액(pH 4.5)중불은정,강해생성아탁벌타정개잡질H,아탁벌타정개편재pH 1.0염산용액중용출속솔최만;결론아탁벌타정개재pH 1.0염산용액중용출곡선가작위처방사선적의거。
Objective To establish the dissolution method of atorvastatin calcium tablets. Methods Column Agilent TC-C18 (4.6×250 mm, 5μm) with mobile phase consisted of acetonitrile: tetrahydrofuran: 0.05 M ammonium citrate buffer pH 4.0 (27:20:53) at a flow rate of 1.5 mL·min-1 when the detective wavelength was set at 244 nm, plus the atorvastatin and atorvastatin related compound H peak area to calculate the cumulative release amount (%); Results Atorvastatin calcium was instable in pH 1.0 hydrochloric acid solution and acetic acid- ammonium acetate buffer (pH 4.5) and degrade to atorvastatin related compound H, the pH 1.0 hydrochloric acid solution dissolution profile of atorvastatin calcium tablets was the slowest one. Conclusion The pH 1.0 hydrochloric acid solution dissolution profile of atorvastatin calcium tablets can be used as the basis for formulation screening.